Avectas

Avectas develops non-viral cell engineering technology for scalable and affordable cell therapy manufacturing. Its Solupore Integrated platform consolidates multiple unit processes, including activation, transduction, expansion, and harvest, into a single closed, automated, sensor-enabled consumable. This approach reduces facility costs by up to 75%, increases throughput by 600%, and lowers cost of goods by up to 25% compared to conventional manufacturing workflows. The platform supports non-viral editing techniques including mRNA, CRISPR, and HDR workflows, producing potent CAR-T cells with stem-like phenotypes and low exhaustion markers. Solupore Integrated features GMP consumables with a Drug Master File filed with the FDA, 21 CFR Part 11 electronic batch records, and a US-established supply chain. Founded in 2011 and headquartered in Dublin, Ireland, the company has raised approximately $33.5 million at the Series C stage, and has partnered with CCRM and OmniaBio to improve cell therapy manufacturing.